June 18, 2007
Dermlex Launch
Analysis of:
Advitech to finally launch Dermylex in US | www.nutraingredients-usa.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: Advitech's launch of Dermylex will not have much of an impact on the psoriasis market. This is due to the fact that the product has minimal studies to back it up, and the company will rely on testimonials. This is not an effective way of marketing to physicians, and is difficult with patients. No "natural" product has sold well for psoriasis in past.
Analysis: This launch will not have much impact on existing products or companies. These companies generally have FDA approved products, which have been present in the marketplace with good sales and marketing support, and clinical trilas to back them up.
Analysis: This launch will not have much impact on existing products or companies. These companies generally have FDA approved products, which have been present in the marketplace with good sales and marketing support, and clinical trilas to back them up.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Painkiller Risk Found for Heart Patients
www.nytimes.com
FDA Asks if Pain Pill Is Tamper-Proof
online.wsj.com
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
www.pipelinereview.com
Hospitals See Drop in Paying Patients
www.nytimes.com
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
www.fiercebiotech.com
Is Celebrex Next ?
November 18, 2008
Will contact lens solutions cost more to ship and store?
November 13, 2008
Economy's impact on healthcare facilities
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
A closer look
November 11, 2008